hexane = 90:10 to 98: 2) to give product 5 in 80% yield (111 mg); Rf = 0.22 (EtOAc : MeOH = 98:2). 1 H-NMR (DMSO-d6) : 12.01 (s, 1H, OH), 8.22 (t, 1H, NH-CH2), 8.07 (d, 1H, kyna ArH), 7.92 (d, 1H, kyna ArH) , 7.69 (t, 1H, kyna ArH), 7.35 (t, 1H, kyna ArH) , 7.21-7.01 (m, 7H, Phe ArH, NH-Boc, Gly NH), 6.73 (s, 1H, kyna ArH) , 5.12 (q, 1H, Phe H  ), 4.34 (d, 2H, Gly H  ), 4.03-3.93 (m, 3H, CH2-O, DAla H  ), 3.50-3.38 (m, 2H, Phe H   2.81 (s, 3H, NCH3), 1.32 (s, 9H, 3*CH3), 1.09 (d, 3H, CH3 DAla) .
Boc-Tyr-DAla-Gly-N(Me) : Intermediate 5 has been deprotected with a mixture of TFA:DCM =1:1 at r.t. for 1h, then the solvent was evaporated in rotavapor and the residue washed with DCM, dried in rotary evaporator repetitively and high vacuum. The so obtained TFA salt was coupled with Boc- 0.2 mmol) following the general procedure of coupling. The crude product has been purified by silica gel column chromatography (from EtOAc 100% to EtOAc : MeOH = 95:5) to give product 6 in 66% yield (104 mg); Rf = 0.18 (EtOAc : MeOH = 98:2). 1 H-NMR (DMSO-d6) : 12.01 (s, 1H, OH), 9.13 (s, 1H, OH Tyr), 8.07 (d, 1H, kyna ArH), 7.95 (d, 1H, kyna ArH) , 7.69 (t, 1H, kyna ArH), 7.35 (t, 1H, kyna ArH), 8.20 (t, 1H, ArH), 7.93 (d, 1H, J = 8.7 Hz, kyna ArH), 7.70 (d, 1H, J = 7.5 Hz, kyna ArH), 7.36 (t, 1H, J = 7.5 Hz, kyna ArH), 5H, Phe ArH), 6.99 (d, 2H, J = 8.4 Boc-Kynurenine (7): This intermediate has been prepared following the procedure reported by Tsentalovich et al. [2] and it has been previously characterized in literature.
Boc-Kynurenine-Phe-NH2 (8): H-Phe-NH2 has been prepared starting from natural amino acid Boc-Phe-OH, following the general procedure of amidation. The so obtained product (91 mg, 0.3 mmol) has been deprotected with a mixture of TFA:DCM =1:1 at r.t. for 1h, then the solvent was evaporated in rotavapor and the residue washed with DCM (3 times), dried in rotary evaporator and high vacuum.
Coupling reaction with Boc-Kyn-OH (116.7, 0.4 mmol) has been performed following the general procedure, to give intermediate peptide 8 in 61% yield (95 mg); Rf = 0.5 (EtOAc 100%). 1 Boc-Pro-Kyn-Phe-NH2 (9): Intermediate compound 8 has been deprotected with a mixture of TFA:DCM =1:1 at r.t. for 1h, then the solvent was evaporated in rotavapor and the residue washed with DCM (3 times), dried in rotary evaporator and high vacuum and allowed to react with Boc-Pro-OH (49.5, 0.2 mmol) following the general procedure of coupling. Intermediate peptide 9 has been obtained in 81% yield (93 mg); Rf = 0.43 (EtOAc 100%). 1 Boc-Tyr-Pro-Kyn-Phe-NH2 (10): Intermediate compound 9 has been deprotected with a mixture of TFA:DCM =1:1 at r.t. for 1h, then the solvent was evaporated in rotavapor and the residue washed with DCM (3 times), dried in high vacuum and allowed to react with Boc-Tyr-OH (52.2 mg, 0.2 mmol) following the general procedure of coupling. The Boc-protected peptide 10 has been obtained in 73% yield (88.7 mg); Rf = 0.15 (EtOAc 100%). 1 Boc-Kyn-NH2 (11): Intermediate 7 has been converted in its amide derivative 11, following the general procedure of amidation (71% yield, 106 mg); Rf = 0.6 (EtOAc 100%). 1 (15): L-Kynurenine (50 mg, 0.2 mmol) was converted in its methyl ester derivative 15, following the procedure described in Stefanucci et al. [3] . The desired product has been obtained quantitatively (53 mg Boc-Gly-Phe-Kyn-OCH3 (17): Intermediate 16 has been treated with a mixture of TFA:DCM = 1:1 at r.t. for 1h, then DCM was removed in rotavapor and the crude residue dried in high vacuum. The so obtained compound was used for the next coupling reaction with BocGly-OH (17.5 mg, 0.1 mmol) without further purification, following the general procedure. The desired peptide 17 has been obtained in quantitative yield after reaction work-up (46.9 mg); Rf = 0.71 (EtOAc 100%). 1 Boc-DAla-Gly-Phe-Kyn-OCH3 (18): Intermediate 17 has been treated with a mixture of TFA:DCM = 1:1 at r.t. for 1h, then DCM was removed in rotavapor and the crude residue dried in high vacuum. The so obtained compound was used for the next coupling reaction with Boc-DAla-OH (20.8 mg, 0.1 mmol) without further purification, following the general procedure. The crude product has been purified by silica gel column chromatography (from EtOAc : n-hexane = 80:20 to 90:10), to give intermediate 16 in 84% yield (50 mg); Rf = 0.32 (EtOAc 100%). 1 
Plasma stability assay
Five calibration standards were injected into the HPLC-UV/Vis system. HPLC analyses were performed on a Waters liquid chromatograph equipped with a model 600 solvent pump and a 2996 photodiode array detector, and the mobile phase was degassed directly on-line by using Degassex, mod. DG-4400 (Phenomenex, Torrance, CA, USA). Empower v2.0 Software (Waters Spa, Milford, MA, USA) was used for data acquisition and elaboration. A reversedphase packing column (XBridge BEH 130 C18, 4.6 × 250 mm, 5 μm; Waters Spa, Milford, MA, USA) was employed for the separation and the column was held at room temperature (22 ± 1 °C). K6 remaining concentrations at different times are reported below. For quantitative analyses, selective detection was performed at 210 nm. Gradient elution mode was performed using a mobile phase containing a 98:1 water-ACN ratio as starting conditions and gradient program as reported.
Time ( All the sample solutions were previously centrifuged and 20 L of the supernatant was injected into the HPLC-UV/Vis system. Calibration curves from 2 to 10 μg/mL were calculated by analyzing five non-zero concentration standards prepared in freshly spiked plasma solution in triplicate and extracted. All quantitative analyses were performed at 210 nm. Calibration curves were linear with r 2 values always greater than 0.988 (n = 3). In reported chromatographic conditions, the retention times for K6 was 16.45 minutes (± 0.4, n = 20), the substance identity was confirmed by LS-MS analysis. 
